Customize Order

Leave This Empty:

Global Cancer Genome Sequencing Market Research Report 2022

choose chapter to purchase

table of content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Genome Sequencing Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Second Generation
1.2.3 Third Generation
1.3 Market by Application
1.3.1 Global Cancer Genome Sequencing Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Treatment
1.3.3 Research
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Cancer Genome Sequencing Market Perspective (2017-2028)
2.2 Cancer Genome Sequencing Growth Trends by Region
2.2.1 Cancer Genome Sequencing Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Cancer Genome Sequencing Historic Market Size by Region (2017-2022)
2.2.3 Cancer Genome Sequencing Forecasted Market Size by Region (2023-2028)
2.3 Cancer Genome Sequencing Market Dynamics
2.3.1 Cancer Genome Sequencing Industry Trends
2.3.2 Cancer Genome Sequencing Market Drivers
2.3.3 Cancer Genome Sequencing Market Challenges
2.3.4 Cancer Genome Sequencing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Genome Sequencing Players by Revenue
3.1.1 Global Top Cancer Genome Sequencing Players by Revenue (2017-2022)
3.1.2 Global Cancer Genome Sequencing Revenue Market Share by Players (2017-2022)
3.2 Global Cancer Genome Sequencing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Genome Sequencing Revenue
3.4 Global Cancer Genome Sequencing Market Concentration Ratio
3.4.1 Global Cancer Genome Sequencing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Genome Sequencing Revenue in 2021
3.5 Cancer Genome Sequencing Key Players Head office and Area Served
3.6 Key Players Cancer Genome Sequencing Product Solution and Service
3.7 Date of Enter into Cancer Genome Sequencing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Genome Sequencing Breakdown Data by Type
4.1 Global Cancer Genome Sequencing Historic Market Size by Type (2017-2022)
4.2 Global Cancer Genome Sequencing Forecasted Market Size by Type (2023-2028)
5 Cancer Genome Sequencing Breakdown Data by Application
5.1 Global Cancer Genome Sequencing Historic Market Size by Application (2017-2022)
5.2 Global Cancer Genome Sequencing Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Cancer Genome Sequencing Market Size (2017-2028)
6.2 North America Cancer Genome Sequencing Market Size by Country (2017-2022)
6.3 North America Cancer Genome Sequencing Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Cancer Genome Sequencing Market Size (2017-2028)
7.2 Europe Cancer Genome Sequencing Market Size by Country (2017-2022)
7.3 Europe Cancer Genome Sequencing Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Genome Sequencing Market Size (2017-2028)
8.2 Asia-Pacific Cancer Genome Sequencing Market Size by Country (2017-2022)
8.3 Asia-Pacific Cancer Genome Sequencing Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Cancer Genome Sequencing Market Size (2017-2028)
9.2 Latin America Cancer Genome Sequencing Market Size by Country (2017-2022)
9.3 Latin America Cancer Genome Sequencing Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Genome Sequencing Market Size (2017-2028)
10.2 Middle East & Africa Cancer Genome Sequencing Market Size by Country (2017-2022)
10.3 Middle East & Africa Cancer Genome Sequencing Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Detail
11.1.2 Agilent Technologies Business Overview
11.1.3 Agilent Technologies Cancer Genome Sequencing Introduction
11.1.4 Agilent Technologies Revenue in Cancer Genome Sequencing Business (2017-2022)
11.1.5 Agilent Technologies Recent Development
11.2 GE Healthcare Life Sciences
11.2.1 GE Healthcare Life Sciences Company Detail
11.2.2 GE Healthcare Life Sciences Business Overview
11.2.3 GE Healthcare Life Sciences Cancer Genome Sequencing Introduction
11.2.4 GE Healthcare Life Sciences Revenue in Cancer Genome Sequencing Business (2017-2022)
11.2.5 GE Healthcare Life Sciences Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Cancer Genome Sequencing Introduction
11.3.4 Johnson & Johnson Revenue in Cancer Genome Sequencing Business (2017-2022)
11.3.5 Johnson & Johnson Recent Development
11.4 LI-COR Biosciences
11.4.1 LI-COR Biosciences Company Detail
11.4.2 LI-COR Biosciences Business Overview
11.4.3 LI-COR Biosciences Cancer Genome Sequencing Introduction
11.4.4 LI-COR Biosciences Revenue in Cancer Genome Sequencing Business (2017-2022)
11.4.5 LI-COR Biosciences Recent Development
11.5 Abbott Laboratories
11.5.1 Abbott Laboratories Company Detail
11.5.2 Abbott Laboratories Business Overview
11.5.3 Abbott Laboratories Cancer Genome Sequencing Introduction
11.5.4 Abbott Laboratories Revenue in Cancer Genome Sequencing Business (2017-2022)
11.5.5 Abbott Laboratories Recent Development
11.6 Beckman Coulter
11.6.1 Beckman Coulter Company Detail
11.6.2 Beckman Coulter Business Overview
11.6.3 Beckman Coulter Cancer Genome Sequencing Introduction
11.6.4 Beckman Coulter Revenue in Cancer Genome Sequencing Business (2017-2022)
11.6.5 Beckman Coulter Recent Development
11.7 Bayer
11.7.1 Bayer Company Detail
11.7.2 Bayer Business Overview
11.7.3 Bayer Cancer Genome Sequencing Introduction
11.7.4 Bayer Revenue in Cancer Genome Sequencing Business (2017-2022)
11.7.5 Bayer Recent Development
11.8 Hamilton Thorne Biosciences
11.8.1 Hamilton Thorne Biosciences Company Detail
11.8.2 Hamilton Thorne Biosciences Business Overview
11.8.3 Hamilton Thorne Biosciences Cancer Genome Sequencing Introduction
11.8.4 Hamilton Thorne Biosciences Revenue in Cancer Genome Sequencing Business (2017-2022)
11.8.5 Hamilton Thorne Biosciences Recent Development
11.9 Integrated DNA Technologies
11.9.1 Integrated DNA Technologies Company Detail
11.9.2 Integrated DNA Technologies Business Overview
11.9.3 Integrated DNA Technologies Cancer Genome Sequencing Introduction
11.9.4 Integrated DNA Technologies Revenue in Cancer Genome Sequencing Business (2017-2022)
11.9.5 Integrated DNA Technologies Recent Development
11.10 Microchip Biotechnologies
11.10.1 Microchip Biotechnologies Company Detail
11.10.2 Microchip Biotechnologies Business Overview
11.10.3 Microchip Biotechnologies Cancer Genome Sequencing Introduction
11.10.4 Microchip Biotechnologies Revenue in Cancer Genome Sequencing Business (2017-2022)
11.10.5 Microchip Biotechnologies Recent Development
11.11 Myriad Genetics
11.11.1 Myriad Genetics Company Detail
11.11.2 Myriad Genetics Business Overview
11.11.3 Myriad Genetics Cancer Genome Sequencing Introduction
11.11.4 Myriad Genetics Revenue in Cancer Genome Sequencing Business (2017-2022)
11.11.5 Myriad Genetics Recent Development
11.12 Commonwealth Biotechnologies
11.12.1 Commonwealth Biotechnologies Company Detail
11.12.2 Commonwealth Biotechnologies Business Overview
11.12.3 Commonwealth Biotechnologies Cancer Genome Sequencing Introduction
11.12.4 Commonwealth Biotechnologies Revenue in Cancer Genome Sequencing Business (2017-2022)
11.12.5 Commonwealth Biotechnologies Recent Development
11.13 ZS Genetics
11.13.1 ZS Genetics Company Detail
11.13.2 ZS Genetics Business Overview
11.13.3 ZS Genetics Cancer Genome Sequencing Introduction
11.13.4 ZS Genetics Revenue in Cancer Genome Sequencing Business (2017-2022)
11.13.5 ZS Genetics Recent Development
11.14 Pacific Biosciences
11.14.1 Pacific Biosciences Company Detail
11.14.2 Pacific Biosciences Business Overview
11.14.3 Pacific Biosciences Cancer Genome Sequencing Introduction
11.14.4 Pacific Biosciences Revenue in Cancer Genome Sequencing Business (2017-2022)
11.14.5 Pacific Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details